sana biotechnology is focused on utilizing engineered cells as medicines for patients. the ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. sana is building differentiated capabilities across the spectrum of cell and gene therapy. three aspirations drive sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. the first is the ability to repair and control the genes in any cell in the body. we are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. last is a belief we can enable broader access to ou
Company profile
Ticker
SANA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Cobalt Biomedicine, Inc. • Oscine Corp. • Cytocardia, Inc. ...
SANA stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
8 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
8 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Departure of Directors or Certain Officers
18 Apr 24
S-3ASR
Automatic shelf registration
1 Mar 24
8-K
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
29 Feb 24
8-K
Sana Biotechnology Announces Pricing of Upsized Public Offering
8 Feb 24
Latest ownership filings
4
Hans Edgar Bishop
8 Apr 24
3
Initial statement of insider ownership
8 Apr 24
SC 13G/A
FMR LLC
3 Apr 24
4
Patrick Y Yang
11 Mar 24
4
DOUGLAS E WILLIAMS
8 Mar 24
4
Steve Harr
8 Mar 24
4
Christian Hordo
8 Mar 24
4
Nathan Hardy
8 Mar 24
4
Bernard J Cassidy
8 Mar 24
SC 13G/A
BAILLIE GIFFORD & CO
7 Mar 24
Financial summary
Quarter (USD) | Mar 24 | Sep 23 | Jun 23 | Mar 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 180.89 mm | 180.89 mm | 180.89 mm | 180.89 mm | 180.89 mm | 180.89 mm |
Cash burn (monthly) | (no burn) | 532.25 k | 36.91 mm | 26.10 mm | 21.88 mm | 22.27 mm |
Cash used (since last report) | n/a | 1.20 mm | 83.01 mm | 58.71 mm | 49.20 mm | 50.09 mm |
Cash remaining | n/a | 179.69 mm | 97.88 mm | 122.18 mm | 131.68 mm | 130.80 mm |
Runway (months of cash) | n/a | 337.6 | 2.7 | 4.7 | 6.0 | 5.9 |
Institutional ownership, Q1 2024
95.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 149 |
Opened positions | 71 |
Closed positions | 10 |
Increased positions | 30 |
Reduced positions | 29 |
13F shares | Current |
---|---|
Total value | 1.35 tn |
Total shares | 210.37 mm |
Total puts | 123.60 k |
Total calls | 297.40 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
ARCH Venture Fund IX | 44.04 mm | $0.00 |
Flagship Pioneering | 25.00 mm | $250.02 bn |
FMR | 22.04 mm | $220.43 bn |
Flagship Ventures Fund V | 21.17 mm | $0.00 |
Vanguard | 12.16 mm | $121.55 bn |
Baillie Gifford & Co | 10.66 mm | $106.56 bn |
Canada Pension Plan Investment Board | 10.18 mm | $101.75 bn |
BLK Blackrock | 9.05 mm | $90.46 bn |
STT State Street | 6.37 mm | $63.70 bn |
Capital World Investors | 5.45 mm | $54.49 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Bishop Hans Edgar | Common Stock | Grant | Acquire A | No | No | 0 | 2,774 | 0.00 | 5,779,640 |
8 Mar 24 | Yang Patrick Y | Common Stock | Sell | Dispose S | No | No | 9.452 | 25,000 | 236.30 k | 149,250 |
7 Mar 24 | Williams Douglas E | Stock Option Common Stock | Grant | Acquire A | No | No | 9.58 | 301,875 | 2.89 mm | 301,875 |
7 Mar 24 | Williams Douglas E | RSU Common Stock | Grant | Acquire A | No | No | 0 | 67,083 | 0.00 | 67,083 |
7 Mar 24 | Steve Harr | Stock Option Common Stock | Grant | Acquire A | No | No | 9.58 | 900,000 | 8.62 mm | 900,000 |
7 Mar 24 | Steve Harr | RSU Common Stock | Grant | Acquire A | No | No | 0 | 200,000 | 0.00 | 200,000 |
News
Sana Biotechnology Showcases Nature Biotechnology Publication Of In Vivo Preclinical Data Demonstrating Potential Of Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation For Treating Huntington's Disease And Other Glial-Based Neurodegenerative Conditions
21 May 24
HC Wainwright & Co. Reiterates Buy on Sana Biotechnology, Maintains $12 Price Target
9 May 24
Sana Biotechnology Q1 Adj $(0.32), Inline
8 May 24
Press releases
Flagship Pioneering Unveils Prologue Medicines to Unlock the Therapeutic Potential of the Viral Proteome
7 May 24
Sana Biotechnology to Present at May and June 2024 Investor Conferences
6 May 24
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
8 Apr 24
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
19 Mar 24